www.oncotarget.com Oncotarget, 2020, Vol. 11, (No. 36), pp: 3387-3404 Research Paper Down syndrome iPSC model: endothelial perspective on tumor development Mariana Perepitchka1,2, Yekaterina Galat1,2,3,*, Igor P. Beletsky3, Philip M. Iannaccone1,2,4,5 and Vasiliy Galat2,3,4,5,6 1Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA 2Developmental Biology Program, Stanley Manne Children’s Research Institute, Ann & Robert H. Lurie Children’s Hospital, Chicago, IL, USA 3Institute of Theoretical and Experimental Biophysics, Russian Academy of Sciences, Pushchino, Russia 4Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA 5Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA 6ARTEC Biotech Inc, Chicago, IL, USA *Co-first author Correspondence to: Mariana Perepitchka, email:
[email protected] Yekaterina Galat, email:
[email protected] Vasiliy Galat, email:
[email protected] Keywords: Down syndrome; iPSC-derived endothelial model; T21 genome-wide Implications; meta-analysis; tumor microenvironment Received: July 10, 2019 Accepted: August 01, 2020 Published: September 08, 2020 Copyright: Perepitchka et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Trisomy 21 (T21), known as Down syndrome (DS), is a widely studied chromosomal abnormality. Previous studies have shown that DS individuals have a unique cancer profile. While exhibiting low solid tumor prevalence, DS patients are at risk for hematologic cancers, such as acute megakaryocytic leukemia and acute lymphoblastic leukemia.